Cover Image
Market Research Report

Global Osteoarthritis Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 823140
Published Content info 125 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Osteoarthritis Therapeutics Market 2019-2023
Published: March 27, 2019 Content info: 125 Pages
Description

About this market

The increasing incidence of osteoarthritis will drive the osteoarthritis therapeutics market growth in the forthcoming years. Rising incidences of aging and obesity will directly contribute to the increasing prevalence of osteoarthritis in both developing and developed regions. Furthermore, the inflammation of adipose tissue and dyslipidemia associated with obesity is further expected to contribute majorly to the osteoarthritis therapeutics market growth in the forthcoming years. Technavio's analysts have predicted that the osteoarthritis therapeutics market will register a CAGR of about 8% by 2023.

Market Overview

Availability of guidelines for disease management

One of the growth drivers of the global osteoarthritis therapeutics market is the availability of guidelines for disease management. This will improvise the patient acceptance of drugs, which, in turn, is expected to drive the market growth.

Side-effects of available drugs

One of the challenges in the growth of the global osteoarthritis therapeutics market is the side-effects of available drugs. The common side-effects associated with available drugs such as constipation, physical dependence, and numbness can limit the adoption of the available drugs.

For the detailed list of factors that will drive and challenge the growth of the osteoarthritis therapeutics market during 019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR31047

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Analgesics and NSAIDs - Market size and forecast 2018-2023
  • Corticosteriods - Market size and forecast 2018-2023
  • Viscosupplements - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Ankle osteoarthritis
  • Hip osteoarthritis
  • Knee osteoarthritis
  • Shoulder osteoarthritis
  • Others

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for osteoarthritis
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Analgesics and NSAIDs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Analgesics and NSAIDs - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Corticosteriods - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Corticosteriods - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Viscosupplements - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Viscosupplements - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bayer AG - Vendor overview
  • Exhibit 49: Bayer AG - Business segments
  • Exhibit 50: Bayer AG - Organizational developments
  • Exhibit 51: Bayer AG - Geographic focus
  • Exhibit 52: Bayer AG - Segment focus
  • Exhibit 53: Bayer AG - Key offerings
  • Exhibit 54: GlaxoSmithKline plc - Vendor overview
  • Exhibit 55: GlaxoSmithKline plc - Business segments
  • Exhibit 56: GlaxoSmithKline plc - Organizational developments
  • Exhibit 57: GlaxoSmithKline plc - Geographic focus
  • Exhibit 58: GlaxoSmithKline plc - Segment focus
  • Exhibit 59: GlaxoSmithKline plc - Key offerings
  • Exhibit 60: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 61: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 62: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 63: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 64: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 65: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 66: Pfizer Inc. - Vendor overview
  • Exhibit 67: Pfizer Inc. - Business segments
  • Exhibit 68: Pfizer Inc. - Organizational developments
  • Exhibit 69: Pfizer Inc. - Geographic focus
  • Exhibit 70: Pfizer Inc. - Segment focus
  • Exhibit 71: Pfizer Inc. - Key offerings
  • Exhibit 72: Sanofi - Vendor overview
  • Exhibit 73: Sanofi - Business segments
  • Exhibit 74: Sanofi - Organizational developments
  • Exhibit 75: Sanofi - Geographic focus
  • Exhibit 76: Sanofi - Segment focus
  • Exhibit 77: Sanofi - Key offerings
  • Exhibit 78: Validation techniques employed for market sizing
Back to Top